<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076423</url>
  </required_header>
  <id_info>
    <org_study_id>GeSIDA 10918</org_study_id>
    <nct_id>NCT04076423</nct_id>
  </id_info>
  <brief_title>A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection</brief_title>
  <acronym>InSTINCT</acronym>
  <official_title>A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      242 patients (121 patients in each of the two treatment arms) will be included with a
      confirmed diagnosis of HIV-1 infection and with a stable antiretroviral treatment during more
      than 48 weeks with dual therapy (DTG + 3TC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparator: the patient will continue taking the dual therapy. Experimental: the patient Will beging to take triple therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sCD14</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>Changes in sCD14 concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in PCR-us</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>Inflammation (IL-6 signaling pathways):</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sCD163</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>Monocyte / macrophage activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quinurenine / tryptophan ratio</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>IDO-1 induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dimer D</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>Coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4/CD8 ratio</measure>
    <time_frame>Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96</time_frame>
    <description>Inmunoactivation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+</measure>
    <time_frame>Throughout all the study, an average of 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in viral suppression rates</measure>
    <time_frame>Throughout all the study, an average of 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal trajectories of plasma biomarkers</measure>
    <time_frame>Throughout all the study, an average of 100 weeks</time_frame>
    <description>The differences in the trajectories of soluble inflammatory markers by comparing the slopes of each biomarker between treatment arms. Longitudinal changes in each biomarker will be compared using linear or non-linear mixed models with random intercepts, depending on the normality of the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal trajectories of CD4/CD8 ratio</measure>
    <time_frame>Throughout all the study, an average of 100 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Experimental arm:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual Therapy</intervention_name>
    <description>DTG + 3TC</description>
    <arm_group_label>Comparator arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple therapy</intervention_name>
    <description>BIC / FTC / TAF</description>
    <arm_group_label>Experimental arm:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years

          -  Confirmed and documented diagnosis of HIV-1 infection

          -  Virological suppression of more than 48 weeks (confirmed with HIV RNA &lt;50 copies /
             ml). The determination of the CV of a routine prior analysis of ≤ 12 weeks prior to
             signature of consent.

          -  ART in stable dual therapy (&gt; 48 weeks) with DTG + 3TC

          -  Signed informed consent

          -  Negative pregnancy test in urine or blood

        Exclusion Criteria:

          -  Inability to obtain written informed consent to participate in the study

          -  Pregnant or breastfeeding women or those who intend to become pregnant during the
             study period and do not undertake to use proven contraceptive methods.

          -  Any suspicion or confirmation of resistance to TAF, 3TC, FTC, DTG or BIC. In case of
             have a study of baseline resistance mutations prior to the start of ART has to rule
             out resistance to investigational drugs.

          -  Patients with hypersensitivity to any excipient used with TAF, FTC, DTG or BIC

          -  Any chronic autoimmune or inflammatory disease

          -  Use of immunomodulatory or immunosuppressive agents, including steroids Chronic
             treatment with aspirin, statins and other anti-inflammatory agents

          -  Any acute infection in the last 2 months

          -  Estimated glomerular filtration rate (TFGe) &lt;30 mg / ml / m2 measured by any of the
             formulas available. The determination of the TFGe of a previous routine analysis of ≤
             12 weeks prior to signing the consent is allowed

          -  Contraindication for the use of TAF

          -  Clinical condition of the patient in rapid deterioration or the investigator considers
             that there is no reasonable hope that the patient will finish the study

          -  Simultaneous participation in another clinical trial or research study that requires
             the need of treatment with other drugs outside the study or interfere with the visits
             of the same.

          -  Any situation that, in the opinion of the investigator, may interfere with the
             patient's ability to meet the treatment schedule and protocol evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Univ. Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Serrano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Univ. Ramón y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquin Portilla, MD</last_name>
      <email>portilla_joa@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Mallolas, MD</last_name>
      <email>MALLOLAS@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Tiraboschi, MD</last_name>
      <phone>+34 932607667</phone>
      <phone_ext>2886</phone_ext>
      <email>jmtiraboschi@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josquín Burgos, MD</last_name>
      <email>jburgos@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Rivero, MD</last_name>
      <email>ariveror@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicente Estrada, MD</last_name>
      <email>vesda001@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfonso Cabello, MD</last_name>
      <email>ACabello@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio De los Santos, MD</last_name>
      <email>isantosg@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Gonzalez, MD</last_name>
      <phone>+34 91 727 70 99</phone>
      <email>juangonzalezgar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Moreno, MD</last_name>
      <phone>+34 913369100</phone>
      <email>smguillen@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Malá</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Pasquau, MD</last_name>
      <phone>+34 958895414</phone>
      <email>jpasquau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel A Castaño, MD</last_name>
      <email>med000849@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Santos, MD</last_name>
      <email>med000854@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Antela, MD</last_name>
      <email>antelacanary@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis F Lopez-Cortes, MD</last_name>
      <email>luisfernando@lopezcortes.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª José Galindo, MD</last_name>
      <email>galindo.pepa1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª Jose Crusells, MD</last_name>
      <email>pcrusells@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

